Cargando…
Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix
Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This m...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201304/ https://www.ncbi.nlm.nih.gov/pubmed/37223767 http://dx.doi.org/10.1016/j.xfre.2023.02.002 |
| _version_ | 1785045238511828992 |
|---|---|
| author | Chwalisz, Kristof |
| author_facet | Chwalisz, Kristof |
| author_sort | Chwalisz, Kristof |
| collection | PubMed |
| description | Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval. |
| format | Online Article Text |
| id | pubmed-10201304 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-102013042023-05-23 Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix Chwalisz, Kristof F S Rep Special Issue Elagolix is the first oral gonadotropin-releasing hormone antagonist that entered clinical development and received regulatory approval for the management of women with endometriosis and heavy menstrual bleeding associated with uterine fibroids in combination with a hormonal add-back therapy. This mini review aims to summarize the key clinical studies that led to its regulatory approval. Elsevier 2023-02-04 /pmc/articles/PMC10201304/ /pubmed/37223767 http://dx.doi.org/10.1016/j.xfre.2023.02.002 Text en © 2023 The Author https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Special Issue Chwalisz, Kristof Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_full | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_fullStr | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_full_unstemmed | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_short | Clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| title_sort | clinical development of the oral gonadotropin-releasing hormone antagonist elagolix |
| topic | Special Issue |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201304/ https://www.ncbi.nlm.nih.gov/pubmed/37223767 http://dx.doi.org/10.1016/j.xfre.2023.02.002 |
| work_keys_str_mv | AT chwaliszkristof clinicaldevelopmentoftheoralgonadotropinreleasinghormoneantagonistelagolix |